Wow, Optune by itself was “good” for recurrent GBM but add Opdivo and suddenly it’s no good. The rigors of a drug based trial versus an external device trial.
NWBO took 16 YEARS to complete a clinical trial. Had a partial stop in the trial. Manipulated the protocol, comparator, endpoints and SAP after the close of the trial. There is NOBODY that has managed a trial so poorly.
NVCR completed their Phase 3 trial with no disruptions and gained approvals by numerous regulators. Let's see what happens with NWBO's dubious trial and an application if they can actually complete one.
Market Data 
Markets 
AI
